iPierian is a pioneering biopharmaceutical company focusing on harnessing the power of induced pluripotent stem cells (iPSCs) to discover novel therapies that are effective in addressing the vast unmet patient needs in neurodegenerative diseases. The company is focused on developing monoclonal antibodies against targets of the Tau protein and the Complement cascade of the innate immune system. The monoclonal antibody development programs evolve from iPierian’s proprietary iPSC technology for disease modeling – utilizing patient-derived cortical neurons, motor neurons, microglia and astrocytes. iPierian is using these human disease models to discover and validate novel targets and molecules to create a pipeline of drug candidates for diseases in neurodegeneration and neuroinflammation. In addition to developing its own proprietary pipeline, iPierian also collaborates with pharmaceutical and biotechnology industry partners.